Comparative study of the performance of GeneXpert MTB/RIF in bronchoalveolar lavage compared to bronchial lavage in patients with clinical suspicion of tuberculosis
Rev. am. med. respir; 21 (3), 2021
Publication year: 2021
Abstract Tuberculosis (TB) is one of the ten leading causes of death worldwide, and the main cause from a single infectious agent. Early detection of the Mycobacterium tuberculosis complex (MTC) and of mutations conferring resistance to the main drugs used in antituberculous treatment contributes to reducing the transmission of the infection, and consequently the spread of resistant TB. The GeneXpert MTB/ RIF test identifies the MTC and simultaneously detects mutations most frequently associated with rifampicin resistance, through real-time PCR testing. The purpose of this study was to compare the performance of the GeneXpert MTB/RIF method in bronchoalveolar lavage (BAL) with bronchial lavage (LB) in immunocompetent patients with clinical suspicion of pulmonary TB without any previous microbiological documentation.